Trial reportFrontiers in immunology2026
Everolimus-based immunosuppression induces alloreactive regulatory T cell expansion combined with loss of alloreactive effector T cells.
Trial report in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mammalian target of rapamycin inhibitors (mTORi) combined with tacrolimus and prednisolone enable tacrolimus dose reduction. This study evaluated everolimus-low-dose tacrolimus-prednisolone (EVR-IS) versus standard myco-phenolate mofetil (MMF)-tacrolimus-prednisolone (MMF-IS) on effector (Teff) and regulatory T cells (Tregs) in elderly kidney transplant recipients. Methods: Blood samples were obtained before, and 12 and 24 months after transplantation in the OPTIMIZE study (EudraCT 2018-003194-10). Recipients ≥ 65 years were randomized to EVR-IS or MMF-IS. Phenotype of circulating T cells (EVR-IS N = 86; MMF-IS N = 83) was assessed by multiparameter flow cytometry including transcription factors. Exploratory immune profiling in a limited cohort of kidney transplant recipients, involved detailed characterization of function and phenotype of donor antigen-specific alloreactive and virus-specific T cells, identified by activation-induced CD137 expression using multiparameter flow cytometry. Treg function was analyzed using a suppression assay after isolation and expansion of Tregs. Results: Effector memory T cells remained stable under EVR-IS but showed a small decline for MMF-IS. Treg frequencies increased in EVR-IS recipients (2.9% to 4.1%, P<0.01). Under EVR-IS, donor antigen-specific alloreactive CD4+ T cells remained stable whereas they declined under MMF-IS. Furthermore, donor antigen-specific alloreactive CD8+ T cells declined more rapidly under EVR-IS than for MMF-IS. Only under EVR-IS donor antigen-specific alloreactive Tregs (3.9% to 5.8%, P = 0.03) increased, which strongly suppressed donor antigen-specific alloreactive effector T-cell proliferation. This led to significantly higher Treg/CD4+Teff (3-fold, P<0.01) and Treg/CD8+Teff (10-fold, P = 0.01) ratios for EVR-IS at M24, respectively. Both regimens reduced polyfunctional donor antigen-specific alloreactive CD4+ T cells during the first year, while proportions of virus-specific T-cells remained unchanged. Conclusion: This study demonstrated that everolimus-combined with low dose tacrolimus and mycophenolate mofetil combined with standard dose of tacrolimus employ different mechanisms to effectively control the alloimmune response facilitating patient-tailored immunosuppression in elderly kidney transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.